RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
AssigneeArrowhead Pharmaceuticals, Inc.
InventorsJon E. Chatterton, David P. Bingaman
Life of this patent
Estimating the term…
Abstract
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Claims19
A composition for attenuating expression of a hypoxia-inducible factor-1α (HIF1A) gene, the composition comprising an interfering RNA having a length of 19 to 49 nucleotides, wherein the interfering RNA comprises a region of at least 13 contiguous nucleotides having at least 90% sequence identity with UAUGUGGAAGUGGCAACUG (SEQ ID NO:
- 53).
Dependencies are inferred from the claim text.